Roivant Sciences (Nasdaq: ROIV) and its subsidiary Pulmovant announced that topline results from the Phase 2 PHocus study of mosliciguat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE